I foolishly was in a crowded indoor location and got COVID (for the third time). I thought about getting Paxlovid. But I ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

You are reading our weekly Well+Being newsletter. Sign up here to get it delivered to your inbox every Thursday. Happy Thursday! Coming up is International Women’s Day on Saturday and the beginning of ...

Preparations are underway for FDA interactions and initiation of Phase 2 studies Data presentation to be provided at the Investor Event on March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March (GLOBE ...

Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests. Paxlovid ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

Paxlovid, a combination of nirmatrelvir and ritonavir, has been shown to reduce hospitalizations and deaths in unvaccinated, high-risk adults. But prior research found it didn’t significantly shorten ...

It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older ...